Protagonist Therapeutics
PTGX
64 hedge funds and large institutions have $189M invested in Protagonist Therapeutics in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 14 closing their positions.
103% more capital invested
Capital invested by funds: $93.2M → $189M (+$96.1M)
7.22% more ownership
Funds ownership: 57.29% → 64.51% (+7.2%)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
3% less funds holding
Funds holding: 66 → 64 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$6.18M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.57M |
| 3 |
VMI
VHCP Management III
New York
|
+$3.41M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.98M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.43M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.56M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.62M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$762K |
| 5 |
SIM
Spark Investment Management
New York
|
-$746K |
PTGX Hedge Fund Activity: Q1 2019 in Review
64 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2019, worth a combined $189M — up 103% from $93.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PTGX and 13 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 24 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $6.18M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.43M sold.
- 64 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2019, down from 66 in Q4 2018.
- Funds reported $189M of Protagonist Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
- 13 funds opened new Protagonist Therapeutics positions in Q1 2019 and 14 closed out, a net change of -1 holder.
- The largest Protagonist Therapeutics buyer in Q1 2019 was Ghost Tree Capital, an estimated $6.18M added.
- The largest Protagonist Therapeutics seller in Q1 2019 was Great Point Partners, an estimated $6.43M sold.
Based on aggregated 13F filings for Q1 2019.